| Description | Thiomyristoyl is an effective and selective SIRT2 inhibitor (IC50: 28 nM). It inhibits SIRT1 (IC50: 98 μM) but no effect on SIRT3 even at 200 μM. |
| In vitro | 在乳腺癌小鼠模型中,Thiomyristoyl可抑制SIRT2及肿瘤生长,并降低c-Myc蛋白水平.Thiomyristoyl的抗癌效应与c-Myc水平降低成正相关. |
| In vivo | Thiomyristoyl对SIRT3/5/6/7抑制效果很弱。Thiomyristoyl可降低体外癌症细胞中c-MYC的水平,在不同细胞系中其对c-MYC水平的降低程度与细胞系本身对Thiomyristoyl的敏感性成正比。 |
| Cell experiments | Human MCF-7 cells are grown in DMEM media contained 10% (vol/vol) heat-inactivated fetal bovine serum and 1% penicillin-streptomycin and treated with in the presence of 200 nM TSA for 6 hr. The acetylation level of p53 protein is determined by western blot using anti-acetyl-p53 (K382) antibody. β-actin serves as a loading control. (Only for Reference) |
| Target activity | SIRT2:28 nM |
| molecular weight | 581.85 |
| Molecular formula | C34H51N3O3S |
| CAS | 1429749-41-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (171.87 mM) Chloroform: Soluble H2O: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Jing H, et al. Cancer Cell. 2016, 29(3):297-310. |